Novo Nordisk (NVO) — Entry Risk Score
Stock · re-scored every trading day · data as of 2026-11-12
The entry score measures one thing: how far Novo Nordisk's price sits from a defensible technical level, on a 30–98 scale. High scores (79+) mean the price has pulled back into a zone where risk can be defined; low scores mean the price is extended above its own trend — not that the stock is bad, but that chasing it here carries undefined risk. The full formula is public on our methodology page.
On 2026-11-12, Novo Nordisk's price sits 0.82 ATR above its 20-day average ($39.83); it trades below its 200-day average ($43.27); its 14-day RSI is 58; it has moved +4.69% over 20 sessions; our regime filter classifies it as no confirmed trend.
Is Novo Nordisk (NVO) a buy right now?
Novo Nordisk scores 68/98 (Hold) as of 2026-11-12; it is 36.5% below its 52-week high of $63.98; it is below its 200-day average; it moved +0.84% over the last 5 sessions. A mid-range score means the price is near its recent average: not a stretched entry, not a discount. Not investment advice.
Score history
Every point is a recorded daily snapshot, committed publicly the evening it was scored — history can't be rewritten after the fact.
| Date | Score | Δ | Close |
|---|---|---|---|
| 2026-11-12 | 68 | +1 | $40.65 |
| 2026-11-06 | 67 | +2 | $40.31 |
| 2026-11-05 | 65 | +31 | $40.30 |
| 2026-11-04 | 34 | -30 | $42.18 |
| 2026-11-03 | 64 | +6 | $40.19 |
| 2026-11-02 | 58 | -15 | $40.45 |
| 2026-10-29 | 73 | -3 | $39.14 |
| 2026-10-28 | 76 | +2 | $38.29 |
| 2026-10-27 | 74 | +7 | $38.67 |
| 2026-10-26 | 67 | -1 | $39.13 |
| 2026-10-23 | 68 | +2 | $39.05 |
| 2026-10-22 | 66 | -3 | $39.43 |
Congress trades in NVO
STOCK Act disclosures by members of Congress, cross-referenced from our Smart Money tracker.
| Traded | Politician | Type | Amount | Return since |
|---|---|---|---|---|
| 2026-09-10 | Kevin Hern (R) | SALE | $1,001 - $15,000 | -8.4% |
| 2026-08-31 | Kevin Hern (R) | SALE | $1,001 - $15,000 | -11.1% |
| 2026-08-26 | Scott Scott Franklin (R) | BUY | $1,001 - $15,000 | -14.6% |
Our analysis mentioning Novo Nordisk
Related stocks
See today's full rankings + entry plan for NVO →Get the Sunday Brief
One email a week, before the open: what the board did, which calls worked, which didn't, and what changed. Free. No spam, unsubscribe anytime.